GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » Effective Interest Rate on Debt %

Scancell Holdings (LSE:SCLP) Effective Interest Rate on Debt %

: 5.01% (As of Oct. 2023)
View and export this data going back to 2010. Start your Free Trial

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Scancell Holdings's annualized positive value of Interest Expense for the quarter that ended in Oct. 2023 was £0.99 Mil. Scancell Holdings's average total debt for the quarter that ended in Oct. 2023 was £19.67 Mil. Therefore, Scancell Holdings's annualized Effective Interest Rate on Debt % for the quarter that ended in Oct. 2023 was 5.01%.


Scancell Holdings Effective Interest Rate on Debt % Historical Data

The historical data trend for Scancell Holdings's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Effective Interest Rate on Debt %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 21.28 10.33 6.30

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
Effective Interest Rate on Debt % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.59 0.73 7.96 8.94 5.01

Competitive Comparison

For the Biotechnology subindustry, Scancell Holdings's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings Effective Interest Rate on Debt % Distribution

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Effective Interest Rate on Debt % falls into.



Scancell Holdings Effective Interest Rate on Debt % Calculation

Scancell Holdings's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Apr. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Apr. 2022 )+Total Debt  (A: Apr. 2023 ))/ count )
=-1  *  -1.215/( (19.028+19.533)/ 2 )
=-1  *  -1.215/19.2805
=6.30 %

where

Total Debt  (A: Apr. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=18.713 + 0.315
=19.028

Total Debt  (A: Apr. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=19.227 + 0.306
=19.533

Scancell Holdings's annualized Effective Interest Rate on Debt % for the quarter that ended in Oct. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Apr. 2023 )+Total Debt  (Q: Oct. 2023 ))/ count )
=-1  *  -0.986/( (19.533+19.815)/ 2 )
=-1  *  -0.986/19.674
=5.01 %

where

Total Debt  (Q: Apr. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=19.227 + 0.306
=19.533

Total Debt  (Q: Oct. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=19.509 + 0.306
=19.815

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Oct. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Scancell Holdings  (LSE:SCLP) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Scancell Holdings Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (LSE:SCLP) Business Description

Industry
Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (LSE:SCLP) Headlines

No Headlines